相关实验视频

Updated: Jul 27, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

关于阿莱克提尼布的最新消息:这是ALK阳性晚期肺癌的第一线治疗方法

Yourong Zhou¹, Yiming Yin¹, Jiangxin Xu^1,2

¹College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

Expert opinion on pharmacotherapy

|June 6, 2023

概括

阿列克提尼布有效地治疗了性淋巴瘤激酶阳性非小细胞肺癌,但会导致严重的不良事件. 需要进一步的研究来管理这些毒性,并开发更安全的替代品.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

阿莱克提尼布是一种第二代形淋巴瘤激酶 (ALK) 氨酸激酶抑制剂 (TKI),用于ALK阳性非小细胞肺癌 (NSCLC).
它显示了重要的和持久的中枢神经系统 (CNS) 反应.
然而,长期使用alectinib与严重的,可能危及生命的不良事件有关,由于缺乏有效干预措施,限制了其临床应用.

研究的目的:

要总结alectinib在ALK阳性NSCLC中的疗效和不良事件.
描述影响alectinib选择的因素.
强调需要管理alectinib诱导的毒性.

主要方法:

在PubMed的文献搜索中,查找从1998年到2023年的临床和基础科学研究论文.
对alectinib疗效和不良事件的临床试验数据的审查.
分析与alectinib相关的心血管,胃肠道,肝胆道,肌肉骨,皮肤和呼吸系统疾病.

主要成果:

阿莱克提尼布在ALK阳性NSCLC中显示出显著的疗效,与第一代ALK抑制剂相比,改善了患者的存活率.
关键不良事件包括心血管,胃肠道,肝胆道,肌肉骨,皮肤和呼吸系统疾病.
严重不良事件的发生限制了alectinib的长期临床使用.

结论:

尽管它有效,但与alectinib相关的严重不良事件限制了其在ALK阳性NSCLC的长期使用.
目前缺乏针对alectinib诱导的不良事件的有效干预措施.
未来的研究应该调查毒性机制,开发临床管理策略,并创建下一代ALK抑制剂,以改善安全性.

关键词:

作为ALK抑制剂的使用.阿莱克提尼布 (Alectinib) 是一种药物.在NSCLCLC中,我们可以看到NSCLCLC.管理策略管理策略关于安全的安全问题

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...